Work

FIGURE 1 from Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma

Year: 2023

Type: other

Abstract: Target lesion change and objective response. Percent change in patient target lesion(s), determined by investigator review of pretreatment and posttreatment imaging, with BOR using criteria from RECIST v1.1. BOR, best overall response; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.

DOI: 10.1158/2767-9764.23713982.v1

Authors: Stephanie L. Alden, Mir Lim, Chester Kao, Daniel Shu, Amit G. Singal, Anne Noonan, Paige Griffith, Marina Baretti, Won Jin Ho, Ihab Kamel, Mark Yarchoan, David Hsiehchen

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4384829187

Cites:

Cited by:

Related to: 10